UTA.14511.CPVT

General#

Cell Line

hPSCreg Name TAUi005-A
Alternative name(s)
UTA.14511.CPVT
Cell line type Human induced pluripotent stem cell (hiPSC)
Last update 17th April 2020
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Tampere University (TAU)
Derivation country Finland

External Databases

BioSamples SAMEA6880681
CLO CLO_0102695

General Information

* Is the cell line readily obtainable for third parties?
Yes
Cell line can only be used in: Fit4purpose-OOC project
Research: allowed
Clinical: not allowed
Commercial: allowed

Donor Information#

General Donor Information

Sex female
Ethnicity Caucasian

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
Catecholaminergic polymorphic ventricular tachycardia
The donor is a carrier of a disease-associated mutation.
Synonyms
  • Double tachycardia induced by catecholamines
  • CPVT
  • Bidirectional tachycardia induced by catecholamine
  • Malignant paroxysmal ventricular tachycardia
  • Multifocal ventricular premature beats
show more synonyms
Genetic variants
RYR2 (target)
q43
NM_001035.2:c.6982C>T
RYR2 mutation P2328S

Karyotyping (Donor)

Has the donor karyotype been analysed?
No

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA6880682

Ethics#

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Do you (Depositor/Provider) hold a copy of the SIGNED Donor Consent Form? Yes
If you do not hold the SIGNED Donor Consent Form, have you obtained a copy of the unsigned Donor Consent Form from the holder? No
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent pertain to a specific research project? No
Does consent permit unforeseen future research, without further consent? Yes
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? No
Does consent expressly prevent development of commercial products? No
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No

Does consent permit research by

an academic institution? Yes
a public organisation? Yes
a non-profit company? Yes
a for-profit corporation? Yes
How may genetic information associated with the cell line be accessed? No information
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? Ethics Committee of Pirkanmaa Hospital District
Approval number R08070
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation#

General

Source cell type
skin fibroblast
Collected in 2016

Reprogramming method

Vector type Non-integrating
Vector Episomal
Genes

Vector free reprogramming

Type of used vector free reprogramming factor(s)
None

Other

Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions#

Surface coating Gelatin
Feeder cells CF-1 MEF MITC
Cellfinder Ont Id: CELDA_00007731
Passage method Enzymatically
Collagenase
CO2 Concentration 5 %
Medium Other medium:
Base medium: KO-DMEM
Main protein source: Knock-out serum replacement
Serum concentration: 20 %
Supplements
FGF %
NEA
Glutamax
Pen/Strep
β-mercaptoethanol
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
No

Characterisation#

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR FACS Enzymatic Assay Expression Profiles
POU5F1 (OCT-4)
Yes
c-MYC
Yes
NANOG
Yes
SOX2
Yes
ZFP42 (REX-1)
Yes
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro spontaneous differentiation
Marker Expressed
Sox17
Yes
AFP
Yes
Protocol or reference
Mesoderm
Ont Id: UBERON_0000926
In vitro spontaneous differentiation
Marker Expressed
KDR
Yes
ACTC1 - alpha cardiac actinin
Yes
Protocol or reference
Ectoderm
Ont Id: UBERON_0000924
In vitro spontaneous differentiation
Marker Expressed
SOX1
Yes
PAX6
Yes
Protocol or reference

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
No

Other Genotyping (Cell Line)